Amgen (AMGN) announced new interim results from the global Phase 3 DeLLphi-304 trial showing IMDELLTRA reduced the risk of death by 40% and significantly extended median overall survival by more than five months compared to standard-of-care chemotherapy in patients with small cell lung cancer who progressed on or after one line of platinum-based chemotherapy. The results will be presented at the 2025 American Society of Clinical Oncology Annual Meeting and have been published in The New England Journal of Medicine.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s Strong Market Position and Growth Potential Drive Buy Rating
- Amgen assumed with a Neutral at Guggenheim
- Amgen price target lowered to $328 from $329 at Piper Sandler
- Biotech Alert: Searches spiking for these stocks today
- Cautious Hold on Amgen: Navigating Competitive Challenges and Market Potential for MariTide
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue